Rhythm Pharmaceuticals Posts Q4 Revenue Beat, Narrows Loss; Shares Edge Higher
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) reported financial results for the fourth quarter and full year of 2025, delivering a top-line revenue figure that slightly exceeded analyst expectations while posting a narrower-than-anticipated loss per share. The commercial-stage biopharmaceutical company, focused on rare neuroendocrine diseases, saw its shares move modestly higher in pre-market trading following the announcement.
Earnings and Revenue Versus Estimates
The company's financial performance for the quarter showed measured progress against Wall Street forecasts.
- Revenue: Rhythm reported Q4 2025 net product revenue of $57.3 million, derived solely from global sales of its lead therapy IMCIVREE® (setmelanotide). This figure came in just above the analyst consensus estimate of approximately $57.2 million.
- Earnings Per Share (EPS): The company reported a net loss per share attributable to common stockholders of $0.73 for the quarter. This loss was less severe than the estimated loss of $0.82 per share that analysts had projected.
For the full year 2025, total net product revenue reached $194.8 million, a significant increase from $130.1 million in 2024. The annual net loss per share improved to $3.11, compared to $4.34 in the prior year.
Market Reaction and Financial Health
In reaction to the earnings release, RYTM shares were up approximately 3.4% in pre-market activity. This positive initial move suggests investor approval of the revenue beat and improved bottom-line performance relative to expectations. The stock's performance over recent weeks has been mixed, showing a slight decline over the past month.
The company's balance sheet strengthened over the course of the year. Cash, cash equivalents, and short-term investments totaled approximately $388.9 million as of December 31, 2025, up from $320.6 million a year earlier. Management stated this cash position is sufficient to fund planned operations for at least the next 24 months.
Business Highlights and Forward Outlook
The earnings report was accompanied by several key business and clinical updates that outline Rhythm's trajectory for 2026.
- Commercial Growth: Global sales of IMCIVREE grew 12% sequentially in Q4, driven by increased patient numbers for Bardet-Biedl syndrome (BBS) treatment and expanded international reimbursement, including new agreements in several Canadian provinces.
- Regulatory Catalyst: The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of March 20, 2026, for its decision on a supplemental New Drug Application (sNDA) for setmelanotide in acquired hypothalamic obesity (HO). A U.S. launch is planned pending approval.
- Pipeline Progress: The company completed a positive end-of-Phase-2 meeting with the FDA for its oral MC4R agonist, bivamelagon, in acquired HO, supported by data showing persistent BMI reductions. A pivotal Phase 3 trial is planned to start by the end of 2026.
- Data Readouts: Several important clinical trial results are expected in the near term, including topline data from a Japanese cohort study and the Phase 3 EMANATE trial in genetically caused MC4R pathway diseases, both anticipated in March 2026.
Financial Guidance and Analyst Expectations
Rhythm provided its first financial guidance for 2026, forecasting Non-GAAP Operating Expenses in the range of $385 million to $415 million. This metric excludes stock-based compensation.
This outlook can be contextualized against current analyst estimates for the coming year. Wall Street is currently modeling full-year 2026 sales of approximately $300.5 million. For the upcoming first quarter of 2026, analysts are estimating sales of about $59.5 million. The company's expense guidance suggests continued significant investment in commercial expansion and clinical development as it seeks to grow its revenue base.
Conclusion
Rhythm Pharmaceuticals' fourth-quarter results reflect a company executing on its commercial plan for its flagship therapy while advancing a dense pipeline of clinical programs. The slight revenue beat and better-than-feared earnings loss, coupled with a robust cash position and a clear slate of near-term catalysts, appear to have resonated positively with investors in early trading. The key focus for the stock in the immediate future will be the FDA's decision on the acquired HO indication in March, which represents a significant potential expansion of its commercial addressable market.
For a detailed look at upcoming earnings dates and analyst estimate revisions, you can review more information here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investing involves risk, including the potential loss of principal.
